Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — 2025 Bloom Burton & Co. Healthcare Investor Conference

26 slides from Satellos Bioscience's conference presentation, May 5, 2025

  1. Slide 1: 2025 Bloom Burton & Co. Healthcare Investor Conference

    © 2025 Satellos Bioscience 2025 Bloom Burton & Co. Healthcare Investor Conference R E G E N E R AT I N G M U S C L E F R O M W I T H I N T M

  2. Slide 2: Legal Disclaimers

    © 2025 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

  3. Slide 3: Satellos: A New Chapter in Treating Muscle Diseases with SAT-3247

    © 2025 Satellos Bioscience Satellos: A New Chapter in Treating Muscle Diseases with SAT-3247  Disruptive science with first-in-class therapeutic potential  Disease modifying approach in areas of enormous unmet need  Well tolerated, easy-to-administer medication Corporate Highlights 1. 2. 3. 4. 5.

  4. Slide 4: Grounded in science. Inspired by need.

    © 2025 Satellos Bioscience Grounded in science. Inspired by need. Our mission is to improve the treatment of Duchenne muscular dystrophy and other devastating muscle diseases by restoring the body’s ability to regenerate muscle. CHARLIE, age 7, living with Duchenne 4

  5. Slide 5: Rewriting the Duchenne Story

    © 2025 Satellos Bioscience Rewriting the Duchenne Story Newborn – 4 years 5 to 7 years 10 to 12 years 13 to 19 years 20+ Slower to sit, stand, or walk, Muscle fibers break down faster More than 70% of boys lose Ventilator support needed; Increasing heart and with early muscle weakness than the body

  6. Slide 6: SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating

    © 2025 Satellos Bioscience SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating Genetic approaches  Administered by infusion or injection  Gene therapy (DNA) or exon skipping (RNA)  Aims to slow disease progression by stabilizing muscle  Limited by exon status or potential immunoge

  7. Slide 7: SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating

    © 2025 Satellos Bioscience SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating Genetic approaches Satellos’s approach  Administered by infusion or injection  Oral, once-daily pill  Gene therapy (DNA) or exon skipping (RNA)  Designed to be safe and tolerable  Aims to slow disease

  8. Slide 8: Large market opportunities for regeneration in DMD and beyond

    © 2025 Satellos Bioscience Large market opportunities for regeneration in DMD and beyond 1. MUSCU LAR 2. M U S C L E 3. CACHE XI A & DYSTROPHIES 3 $20+B TRAUMA 1 , 2 $10+B AGING $10+B Opportunity: Opportunity: Opportunity:  Duchenne Muscular  66M trauma visits  20% of cancer deaths Dystrophy (DMD

  9. Slide 9: Restoring Repair and Regeneration

    © 2025 Satellos Bioscience Restoring Repair and Regeneration

  10. Slide 10: Landmark Discovery: DMD a Disease of Failed Regeneration

    © 2025 Satellos Bioscience Landmark Discovery: DMD a Disease of Failed Regeneration Michael Rudnicki, OC, PhD, FRS, FRSC Satellos Scientific Founder and Chief Discovery Officer 10

  11. Slide 11: Landmark Discovery: DMD a Disease of Failed Regeneration

    © 2025 Satellos Bioscience Landmark Discovery: DMD a Disease of Failed Regeneration Satellos Approach: Reset regeneration with SAT-3247 Michael Rudnicki, OC, PhD, FRS, FRSC Satellos Scientific Founder and Chief Discovery Officer Numb 2x10-12 3247 AAK1 Mitosis Initiated Damage Muscle Stem Cells 1. No

  12. Slide 12: SAT-3247 Restores Muscle Strength in Canine Model of DMD to Normative Levels

    © 2025 Satellos Bioscience SAT-3247 Restores Muscle Strength in Canine Model of DMD to Normative Levels SAT-3247 treated vs. historical controls Flexion Tetanic Torque Satellos Canine Study  4-months of dosing  2 animals: ~9 months of age at outset  Retriever cross with natural DMD mutation  Ora

  13. Slide 13: SAT-3247 Treatment Shows Evidence of Repair and Regeneration in Canine DMD

    © 2025 Satellos Bioscience SAT-3247 Treatment Shows Evidence of Repair and Regeneration in Canine DMD 500um 500um SAT-3247 Study SAT-3247 Study Healthy Age-Matched DMD Animal / Pre-Treatment DMD Animal / Post-Treatment Non-DMD Comparator Bicep Femoris Bicep Femoris Bicep Femoris 13

  14. Slide 14: Regenerative Index and Inflammatory Markers Offer Potential for Use in Clinical Development

    © 2025 Satellos Bioscience Regenerative Index and Inflammatory Markers Offer Potential for Use in Clinical Development Regenerative Index (RI) Effects on Inflammatory Markers Cytokine % Change Decrease GM-CSF -73 IL-7 -70 IL-18 -62 IL-2 -56 eMHC/IgG IL-6 -53 IL-15 -38 KC-Like -36 500um MCP-1 (CCL2)

  15. Slide 15: Advancing SAT-3247 into Clinical Development

    © 2025 Satellos Bioscience Advancing SAT-3247 into Clinical Development

  16. Slide 16: SAT-3247 Phase 1 First-in-Human Clinical Study

    © 2025 Satellos Bioscience SAT-3247 Phase 1 First-in-Human Clinical Study Healthy Volunteers (n=72) Adults with DMD SAD MAD Crossover Food Effect Multiple Dosing  10 - 400 mg  60 - 240 mg  150 mg  60 mg  5 cohorts of 8  5 cohorts of 8  1 cohort of 8  1 cohort of up to 10  Single dose / 1 da

  17. Slide 17: SAT-3247 Appears Safe and Tolerable in Healthy Volunteer Study

    © 2025 Satellos Bioscience SAT-3247 Appears Safe and Tolerable in Healthy Volunteer Study1 Single Ascending Dose Multiple Ascending Dose No clinically significant findings observed in No clinically significant findings observed in 60, 10, 50, 150, 300 and 400 mg doses. 120, 180, 240 mg doses: Labs L

  18. Slide 18: SAT-3247 Achieved Target PK Profile and Dose Range in Humans Set by Satellos

    © 2025 Satellos Bioscience SAT-3247 Achieved Target PK Profile and Dose Range in Humans Set by Satellos SAT-3247 PK Profile PK Targets Met:  Dose proportional exposure levels  Drug clearance within 24 hours 18

  19. Slide 19: SAT-3247 Achieved Target PK Profile and Dose Range in Humans Set by Satellos

    © 2025 Satellos Bioscience SAT-3247 Achieved Target PK Profile and Dose Range in Humans Set by Satellos SAT-3247 PK Profile SAT-3247 Dose Range 150mg 50mg PK Targets Met: Dose Targets Met:  Dose proportional exposure levels  Exposure ≥IC50 for 6-8 hours  Drug clearance within 24 hours  Peak expo

  20. Slide 20: Overview of Ongoing and Planned Clinical Trials

    © 2025 Satellos Bioscience Overview of Ongoing and Planned Clinical Trials 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Ongoing Phase 1 Program (Underway: Australia) • Ph 1a Presented at • 72 HVs • SAD/MAD/FE MDA/2025 • Ph 1b • Up to 10 Adult DMD Patients Q2 Data • Safety + PK | 28 day Reporting • Ph 1b • Long

  21. Slide 21: Overview of Ongoing and Planned Clinical Trials

    © 2025 Satellos Bioscience Overview of Ongoing and Planned Clinical Trials 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Ongoing Phase 1 Program (Underway: Australia) • Ph 1a Presented at • 72 HVs • SAD/MAD/FE MDA/2025 • Ph 1b • Up to 10 Adult DMD Patients Q2 Data • Safety + PK | 28 day Reporting • Ph 1b • Long

  22. Slide 22: Inside Satellos

    © 2025 Satellos Bioscience Inside Satellos Our company and the team leading it forward

  23. Slide 23: Satellos At a Glance

    © 2025 Satellos Bioscience Satellos At a Glance Background  TSX: MSCL  Founded in 2018 by repeat entrepreneurs  Went public in 2021; uplisted to TSX in 2023  CDN$125M raised to-date  15% insider, 50%+ institutionally held  165M shares o/s, 242M fully diluted  Venture philanthropy partner: PPM

  24. Slide 24: Satellos At a Glance: Planned 2025 Milestones

    © 2025 Satellos Bioscience Satellos At a Glance Background Planned 2025 Milestones  TSX: MSCL Q1: Ph 1a data presented at MDA  Founded in 2018 by repeat entrepreneurs Q2: Ph 1b data in adults with DMD at upcoming conference  Went public in 2021; uplisted to TSX in 2023 Q3: Initial dosing of patie

  25. Slide 25: Satellos Has Built a World-Caliber Team

    © 2025 Satellos Bioscience Satellos Has Built a World-Caliber Team Frank Gleeson, MBA Michael Rudnicki, OC, PhD, FRS Liz Williams, CPA, CA Courtney Wells Philip Lambert, PhD Ryan Mitchell, PhD Co-Founder & Chief Co-Founder & Chief Chief Financial Officer SVP – Clinical Chief Scientific Officer SVP –

  26. Slide 26: © 2025 Satellos Bioscience

    © 2025 Satellos Bioscience 26

Satellos Bioscience — 2025 Bloom Burton & Co. Healthcare Investor Conference on 6ix